



## Medicrea Releases Annual Sales For 2016

**Lyon and New York, January 12th, 2017** - The MEDICREA Group (Alternext Paris: FR0004178572 - ALMED), worldwide leader pioneering the development and manufacture of personalized analytical services and implant solutions for the treatment of complex spinal conditions, announces its 2016 annual sales.

€ millions	2015	2016	Δ
Year to date September 2016	20.9	21.6	+3%
4 <sup>th</sup> Quarter	6.9	7.8	+13%
<b>TOTAL</b>	<b>27.8</b>	<b>29.4</b>	<b>+6%</b>

*Variations in foreign currency rates had no significant impact on 2016 annual sales.*

Group Sales reached a total of €29.4 million in 2016, generating a 6% growth compared to the previous year. 4<sup>th</sup> quarter sales increased 13% compared to the same period of 2015, in line with the accelerated adoption of Medicrea's patient-specific UNiD™ technology, notably in the United States where for the entire year the number of surgeries performed with personalized rods implants have increased by 106% compared to 2015.

The [1,000<sup>th</sup> UNiD™ Rod](#) milestone was achieved in November (almost 1,100 surgeries performed by the end of the year) closely tracking the launch of the company's [Lifetime Warranty](#) on UNiD™ Rod constructs.

**Next publication:** 2016 annual results published March 29, 2017, after market.

### About MEDICREA ([www.medicrea.com](http://www.medicrea.com))

MEDICREA specializes in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. Through the lens of predictive medicine, MEDICREA leads the design, integrated manufacture, and distribution of 30+ FDA approved implant technologies, utilized in over 100k spinal surgeries to date. Operating in a \$10 billion marketplace, MEDICREA is an SME with 160 employees worldwide, which includes 55 at its USA Corp. subsidiary in NYC. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

By leveraging its proprietary software analysis tools with big data and deep learning technologies supported by an expansive collection of clinical and scientific data, MEDICREA is well-placed to streamline the efficiency of spinal care, reducing procedural complications and limiting time spent in the O.R.

For further information, please visit: [medicrea.com](http://medicrea.com).

### Connect with MEDICREA:

[FACEBOOK](#) | [INSTAGRAM](#) | [TWITTER](#) | [WEBSITE](#) | [YOUTUBE](#)

### MEDICREA

Denys Sournac  
Founder, Chairman and CEO  
[dsournac@medicrea.com](mailto:dsournac@medicrea.com)

Fabrice Kilfiger,  
Chief Financial Officer  
[fkilfiger@medicrea.com](mailto:fkilfiger@medicrea.com)  
Tel: +33 (0)4 72 01 87 87

**MEDICREA is listed on ALTERNEXT**  
**Paris ISIN: FR 0004178572 –**  
**Ticker: ALMED**

